Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology

Journal of Lipid Research

Volumn 49, Issue 3, 2008, Pages 499-509

  Schmuth, Matthias ^a,b   Jiang, Yan J ^b,c   Dubrac, Sandrine ^b   Elias, Peter M ^a   Feingold, Kenneth R ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer; Cutaneous; Differentiation; Inflammation; Permeability barrier; Proliferation; Skin; Stratum corneum; Transcription factor

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ABC TRANSPORTER A1; CHOLESTEROL DERIVATIVE; CHOLESTEROL SULFATE; CIGLITAZONE; CYCLOHEXIMIDE; ETRETIN; FILAGGRIN; GW 1514; INVOLUCRIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LORICRIN; OXYSTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; ROSIGLITAZONE; SKIN LIPID; THIOACETIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; CELL RECEPTOR; DNA BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

APOPTOSIS; ATOPIC DERMATITIS; BODY BUILD; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; EPIDERMIS; FETUS DEVELOPMENT; HOMEOSTASIS; HUMAN; IRRITANT DERMATITIS; KERATINOCYTE; LAMELLAR BODY; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; NONHUMAN; ONTOGENY; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN ALLERGY; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; STRATUM CORNEUM; CHEMISTRY; CYTOLOGY; METABOLISM; PHYSIOLOGY; SKIN;

DNA-BINDING PROTEINS; HUMANS; KERATINOCYTES; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SKIN; SKIN DISEASES;

EID: 42949178186     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R800001-JLR200     Document Type: Review

References (119)

1. Schon, M. P., and W. H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899-1912.
2. Koo, J. 1996. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. 14: 485-496.
3. Naldi, L. 2004. Epidemiology of psoriasis. Curr. Drug Targets. 3: 121-128.
4. Leung, D. Y., and T. Bieber. 2003. Atopic dermatitis. Lancet. 361: 151-160.
5. Baurecht, H., A. D. Irvine, N. Novak, T. Illig, B. Buhler, J. Ring, S. Wagenpfeil, and S. Weidinger. 2007. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J. Allergy Clin. Immunol. 120: 1406-1412.
6. Palmer, C. N., A. D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S. P. Lee, D. R. Goudie, A. Sandilands, L. E. Campbell, F. J. Smith, et al. 2006. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38: 441-446.
7. Sandilands, A., A. Terron-Kwiatkowski, P. R. Hull, G. M. O'Regan, T. H. Clayton, R. M. Watson, T. Carrick, A. T. Evans, H. Liao, Y. Zhao, et al. 2007. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat. Genet. 39: 650-654.
8. Bongartz, T., B. Coras, T. Vogt, J. Scholmerich, and U. Muller-Ladner. 2005. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 44: 126-129.
9. Ellis, C. N., J. Varani, G. J. Fisher, M. E. Zeigler, H. A. Pershadsingh, S. C. Benson, Y. Chi, and T. W. Kurtz. 2000. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch. Dermatol. 136: 609-616.
10. Robertshaw, H., and P. S. Friedmann. 2005. Pioglitazone: a promising therapy for psoriasis. Br. J. Dermatol. 152: 189-191.
11. Venkatraman, M. S., A. Chittiboyina, J. Meingassner, C. I. Ho, J. Varani, C. N. Ellis, M. A. Avery, H. A. Pershadsingh, T. W. Kurtz, and S. C. Benson. 2004. Alpha-lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch. Dermatol. Res. 296: 97-104.
12. Varani, J., N. Bhagavathula, C. N. Ellis, and H. A. Pershadsingh. 2006. Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opin. Investig. Drugs. 15: 1453-1468.
13. Schmuth, M., R. E. Watson, D. Deplewski, S. Dubrac, C. C. Zouboulis, and C. E. Griffiths. 2007. Nuclear hormone receptors in human skin. Horm. Metab. Res. 39: 96-105.
14. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57: 43-66.
15. Diepgen, T. L., and V. Mahler. 2002. The epidemiology of skin cancer. Br. J. Dermatol. 146 (Suppl. 61): 1-6.
16. Icre, G., W. Wahli, and L. Michalik. 2006. Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis. J. Invest. Dermatol. 11: 30-35.
17. Michalik, L., and W. Wahli. 2007. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim. Biophys. Acta. 1771: 991-998.
18. Smith, K. R., and D. M. Thiboutot. 2007. Sebaceous gland lipids: friend or foe? J. Lipid Res. 48: In press.
19. Bookout, A. L., Y. Jeong, M. Downes, R. T. Yu, R. M. Evans, and D. J. Mangelsdorf. 2006. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 126: 789-799.
20. Ghosh, A. K., S. Bhattacharyya, G. Lakos, S. J. Chen, Y. Mori, and J. Varga. 2004. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 50: 1305-1318.
21. Li, Y., C. Bolten, B. G. Bhat, J. Woodring-Dietz, S. Li, S. K. Prayaga, C. Xia, and D. S. Lala. 2002. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16: 506-514.
22. Alestas, T., R. Ganceviciene, S. Fimmel, K. Muller-Decker, and C. C. Zouboulis. 2006. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J. Mol. Med. 84: 75-87.
23. Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 137: 354-366.
24. Downie, M. M., D. A. Sanders, L. M. Maier, D. M. Stock, and T. Kealey. 2004. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. Br. J. Dermatol. 151: 766-775.
25. Kim, M. J., D. Deplewski, N. Ciletti, S. Michel, U. Reichert, and R. L. Rosenfield. 2001. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol. Genet. Metab. 74: 362-369.
26. Russell, L. E., W. J. Harrison, A. W. Bahta, C. C. Zouboulis, J. M. Burrin, and M. P. Philpott. 2007. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp. Dermatol. 16: 844-852.
27. Billoni, N., B. Buan, B. Gautier, C. Collin, O. Gaillard, Y. F. Mahe, and B. A. Bernhard. 2000. Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth. Acta Derm. Venereol. 80: 329-334.
28. Nguyen, H., M. Rendl, and E. Fuchs. 2006. Tcf3 governs stem cell features and represses cell fate determination in skin. Cell. 127: 171-183.
29. Braissant, O., and W. Wahli. 1998. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology. 139: 2748-2754.
30. Michalik, L., B. Desvergne, N. S. Tan, S. Basu-Modak, P. Escher, J. Rieusset, J. M. Peters, G. Kaya, F. J. Gonzalez, J. Zakany, et al. 2001. Impaired skin wound healing in peroxisome proliferatoractivated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154: 799-814.
31. Matsuura, H., H. Adachi, R. C. Smart, X. Xu, J. Arata, and A. M. Jetten. 1999. Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol. Cell. Endocrinol. 147: 85-92.
32. Rivier, M., I. Safonova, P. Lebrun, C. E. Griffiths, G. Ailhaud, and S. Michel. 1998. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J. Invest. Dermatol. 111: 1116-1121.
33. Westergaard, M., J. Henningsen, M. L. Svendsen, C. Johansen, U. B. Jensen, H. D. Schroder, I. Kratchmarova, R. K. Berge, L. Iversen, L. Bolund, et al. 2001. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116: 702-712.
34. Hanley, K., L. G. Komuves, N. M. Bass, S. S. He, Y. Jiang, D. Crumrine, R. Appel, M. Friedman, J. Bettencourt, K. Min, et al. 1999. Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J. Invest. Dermatol. 113: 788-795.
35. Komuves, L. G., M. Schmuth, A. J. Fowler, P. M. Elias, K. Hanley, M. Q. Man, A. H. Moser, J. M. Lobaccaro, M. L. Williams, D. J. Mangelsdorf, et al. 2002. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J. Invest. Dermatol. 118: 25-34.
36. Angeli, V., H. Hammad, B. Staels, M. Capron, B. N. Lambrecht, and F. Trottein. 2003. Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. J. Immunol. 170: 5295-5301.
37. Dubrac, S., P. Stoitzner, D. Pirkebner, A. Elentner, K. Schoonjans, J. Auwerx, S. Saeland, P. Hengster, P. Fritsch, N. Romani, et al. 2007. Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function. J. Immunol. 178: 4362-4372.
38. Kang, H. Y., E. Chung, M. Lee, Y. Cho, and W. H. Kang. 2004. Expression and function of peroxisome proliferator-activated receptors in human melanocytes. Br. J. Dermatol. 150: 462-468.
39. Beigneux, A. P., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2000. The acute phase response is associated with retinoid X receptor repression in rodent liver. J. Biol. Chem. 275: 16390-16399.
40. Feingold, K., M. S. Kim, J. Shigenaga, A. Moser, and C. Grunfeld. 2004. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am. J. Physiol. 286: E201-E207.
41. Lu, B., A. H. Moser, J. K. Shigenaga, K. R. Feingold, and C. Grunfeld. 2006. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. J. Lipid Res. 47: 2179-2190.
42. Tan, N. S., L. Michalik, N. Noy, R. Yasmin, C. Pacot, M. Heim, B. Fluhmann, B. Desvergne, and W. Wahli. 2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15: 3263-3277.
43. Schmuth, M., C. M. Haqq, W. J. Cairns, J. C. Holder, S. Dorsam, S. Chang, P. Lau, A. J. Fowler, G. Chuang, A. H. Moser, et al. 2004. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. 122: 971-983.
44. Westergaard, M., J. Henningsen, C. Johansen, S. Rasmussen, M. L. Svendsen, U. B. Jensen, H. D. Schroder, B. Staels, L. Iversen, L. Bolund, et al. 2003. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J. Invest. Dermatol. 121: 1104-1117.
45. Plager, D. A., A. A. Leontovich, S. A. Henke, M. D. Davis, M. T. McEvoy, G. F. Sciallis, 2nd, and M. R. Pittelkow. 2007. Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp. Dermatol. 16: 28-36.
46. Lo Verme, J., J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, andD. Piomelli. 2005. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67: 15-19.
47. Sheu, M. Y., A. J. Fowler, J. Kao, M. Schmuth, K. Schoonjans, J. Auwerx, J. W. Fluhr, M. Q. Man, P. M. Elias, and K. R. Feingold. 2002. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J. Invest. Dermatol. 118: 94-101.
48. Kippenberger, S., S. M. Loitsch, M. Grundmann-Kollmann, S. Simon, T. A. Dang, K. Hardt-Weinelt, R. Kaufmann, and A. Bernd. 2001. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J. Invest. Dermatol. 117: 1430-1436.
49. Kim, D. J., M. T. Bility, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters. 2006. PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13: 53-60.
50. Kim, D. J., K. S. Prabhu, F. J. Gonzalez, and J. M. Peters. 2006. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis. 27: 1105-1112.
51. Man, M. Q., G. D. Barish, M. Schmuth, D. Crumrine, Y. Barak, S. Chang, Y. Jiang, R. M. Evans, P. M. Elias, and K. R. Feingold. 2007. Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J. Invest. Dermatol. In press.
52. Peters, J. M., S. S. Lee, W. Li, J. M. Ward, O. Gavrilova, C. Everett, M. L. Reitman, L. D. Hudson, and F. J. Gonzalez. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol. 20: 5119-5128.
53. Mao-Qiang, M., A. J. Fowler, M. Schmuth, P. Lau, S. Chang, B. E. Brown, A. H. Moser, L. Michalik, B. Desvergne, W. Wahli, et al. 2004. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J. Invest. Dermatol. 123: 305-312.
54. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
55. Fowler, A. J., M. Y. Sheu, M. Schmuth, J. Kao, J. W. Fluhr, L. Rhein, J. L. Collins, T. M. Willson, D. J. Mangelsdorf, P. M. Elias, et al. 2003. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 120: 246-255.
56. Joseph, S. B., A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9: 213-219.
57. Eckert, R. L. 1989. Structure, function, and differentiation of the keratinocyte. Physiol. Rev. 69: 1316-1346.
58. Fuchs, E. 1990. Epidermal differentiation: the bare essentials. J. Cell Biol. 111: 2807-2814.
59. Elias, P. M., M. Schmuth, Y. Uchida, R. H. Rice, M. Behne, D. Crumrine, K. R. Feingold, and W. M. Holleran. 2002. Basis for the permeability barrier abnormality in lamellar ichthyosis. Exp. Dermatol. 11: 248-256.
60. Schmuth, M., J. W. Fluhr, D. C. Crumrine, Y. Uchida, J. P. Hachem, M. Behne, D. G. Moskowitz, A. M. Christiano, K. R. Feingold, and P. M. Elias. 2004. Structural and functional consequences of loricrin mutations in human loricrin keratoderma (Vohwinkel syndrome with ichthyosis). J. Invest. Dermatol. 122: 909-922.
61. Hanley, K., Y. Jiang, S. S. He, M. Friedman, P. M. Elias, D. D. Bikle, M. L. Williams, and K. R. Feingold. 1998. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J. Invest. Dermatol. 110: 368-375.
62. Hanley, K., L. G. Komuves, D. C. Ng, K. Schoonjans, S. S. He, P. Lau, D. D. Bikle, M. L. Williams, P. M. Elias, J. Auwerx, et al. 2000. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J. Biol. Chem. 275: 11484-11491.
63. Kim, S., I. Hong, J. S. Hwang, J. K. Choi, H. S. Rho, D. H. Kim, I. Chang, S. H. Lee, M. O. Lee, and J. S. Hwang. 2006. Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin. Mol. Med. 12: 17-24.
64. Komuves, L. G., K. Hanley, A. M. Lefebvre, M. Q. Man, D. C. Ng, D. D. Bikle, M. L. Williams, P. M. Elias, J. Auwerx, and K. R. Feingold. 2000. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J. Invest. Dermatol. 115: 353-360.
65. Lee, H. K., G. W. Nam, S. H. Kim, and S. H. Lee. 2006. Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. Exp. Dermatol. 15: 66-73.
66. Lim, S. W., S. P. Hong, S. W. Jeong, B. Kim, H. Bak, H. C. Ryoo, S. H. Lee, and S. K. Ahn. 2007. Simultaneous effect of ursolic acid and oleanolic acid on epidermal permeability barrier function and epidermal keratinocyte differentiation via peroxisome proliferator-activated receptor-alpha. J. Dermatol. 34: 625-634.
67. Thuillier, P., A. R. Brash, J. P. Kehrer, J. B. Stimmel, L. M. Leesnitzer, P. Yang, R. A. Newman, and S. M. Fischer. 2002. Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem. J. 366: 901-910.
68. Hanley, K., D. C. Ng, S. S. He, P. Lau, K. Min, P. M. Elias, D. D. Bikle, D. J. Mangelsdorf, M. L. Williams, and K. R. Feingold. 2000. Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J. Invest. Dermatol. 114: 545-553.
69. Schmuth, M., P. M. Elias, K. Hanley, P. Lau, A. Moser, T. M. Willson, D. D. Bikle, and K. R. Feingold. 2004. The effect of LXR activators on AP-1 proteins in keratinocytes. J. Invest. Dermatol. 123: 41-48.
70. Jang, S. I., and P. M. Steinert. 2002. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J. Biol. Chem. 277: 42268-42279.
71. Jessen, B. A., Q. Qin, and R. H. Rice. 2000. Functional AP1 and CRE response elements in the human keratinocyte transglutaminase promoter mediating Whn suppression. Gene. 254: 77-85.
72. Rossi, A., S. I. Jang, R. Ceci, P. M. Steinert, and N. G. Markova. 1998. Effect of AP1 transcription factors on the regulation of transcription in normal human epidermal keratinocytes. J. Invest. Dermatol. 110: 34-40.
73. Dai, X., K. Sayama, Y. Shirakata, Y. Hanakawa, K. Yamasaki, S. Tokumaru, L. Yang, X. Wang, S. Hirakawa, M. Tohyama, et al. 2007. STAT5a/PPARgamma pathway regulates involucrin expression in keratinocyte differentiation. J. Invest. Dermatol. 127: 1728-1735.
74. Nickoloff, B. J., J. Z. Qin, V. Chaturvedi, M. F. Denning, B. Bonish, and L. Miele. 2002. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ. 9: 842-855.
75. Feingold, K. R. 2007. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 48: 2531-2546.
76. Man, M. Q., E. H. Choi, M. Schmuth, D. Crumrine, Y. Uchida, P. M. Elias, W. M. Holleran, and K. R. Feingold. 2006. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J. Invest. Dermatol. 126: 386-392.
77. Calleja, C., N. Messaddeq, B. Chapellier, H. Yang, W. Krezel, M. Li, D. Metzger, B. Mascrez, K. Ohta, H. Kagechika, et al. 2006. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev. 20: 1525-1538.
78. Rivier, M., I. Castiel, I. Safonova, G. Ailhaud, and S. Michel. 2000. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J. Invest. Dermatol. 114: 681-687.
79. Hovnanian, A. 2005. Harlequin ichthyosis unmasked: a defect of lipid transport. J. Clin. Invest. 115: 1708-1710.
80. Akiyama, M., Y. Sugiyama-Nakagiri, K. Sakai, J. R. McMillan, M. Goto, K. Arita, Y. Tsuji-Abe, N. Tabata, K. Matsuoka, R. Sasaki, et al. 2005. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J. Clin. Invest. 115: 1777-1784.
81. Kelsell, D. P., E. E. Norgett, H. Unsworth, M. T. Teh, T. Cullup, C. A. Mein, P. J. Dopping-Hepenstal, B. A. Dale, G. Tadini, P. Fleckman, et al. 2005. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am. J. Hum. Genet. 76: 794-803.
82. Jiang, Y. J., B. Lu, P. Kim, G. Paragh, G. Schmitz, P. M. Elias, and K. R. Feingold. 2008. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J. Invest. Dermatol. 128: 104-109.
83. Holleran, W. M., Y. Takagi, G. K. Menon, G. Legler, K. R. Feingold, and P. M. Elias. 1993. Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function. J. Clin. Invest. 91: 1656-1664.
84. Elias, P. M., D. Crumrine, U. Rassner, J. P. Hachem, G. K. Menon, W. Man, M. H. Choy, L. Leypoldt, K. R. Feingold, and M. L. Williams. 2004. Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J. Invest. Dermatol. 122: 314-319.
85. Strott, C. A., and Y. Higashi. 2003. Cholesterol sulfate in human physiology: what's it all about? J. Lipid Res. 44: 1268-1278.
86. Jiang, Y. J., P. Kim, P. M. Elias, and K. R. Feingold. 2005. LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. J. Lipid Res. 46: 2657-2666.
87. Jiang, Y. J., B. Lu, P. Kim, P. M. Elias, and K. R. Feingold. 2006. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J. Lipid Res. 47: 2248-2258.
88. Hanley, K., Y. Jiang, D. Crumrine, N. M. Bass, R. Appel, P. M. Elias, M. L. Williams, and K. R. Feingold. 1997. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J. Clin. Invest. 100: 705-712.
89. Schmuth, M., K. Schoonjans, Q. C. Yu, J. W. Fluhr, D. Crumrine, J. P. Hachem, P. Lau, J. Auwerx, P. M. Elias, and K. R. Feingold. 2002. Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J. Invest. Dermatol. 119: 1298-1303.
90. Denda, M., L. C. Wood, S. Emami, C. Calhoun, B. E. Brown, P. M. Elias, and K. R. Feingold. 1996. The epidermal hyperplasia associated with repeated barrier disruption by acetone treatment or tape stripping cannot be attributed to increased water loss. Arch. Dermatol. Res. 288: 230-238.
91. Komuves, L. G., K. Hanley, M. Q. Man, P. M. Elias, M. L. Williams, and K. R. Feingold. 2000. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J. Invest. Dermatol. 115: 361-367.
92. Yang, Q., A. Yamada, S. Kimura, J. M. Peters, and F. J. Gonzalez. 2006. Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J. Invest. Dermatol. 126: 374-385.
93. Lee, S. S., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez-Salguero, H. Westphal, and F. J. Gonzalez. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
94. Dubrac, S., and M. Schmuth. 2006. (P)PARsing epidermal development. J. Invest. Dermatol. 126: 241-242.
95. Burdick, A. D., M. T. Bility, E. E. Girroir, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters. 2007. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19: 1163-1171.
96. Burdick, A. D., D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters. 2006. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell. Signal. 18: 9-20.
97. Kim, D. J., I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters. 2005. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280: 9519-9527.
98. Martinasso, G., M. Maggiora, A. Trombetta, R. A. Canuto, and G. Muzio. 2006. Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544. J. Toxicol. Environ. Health. 69: 353-365.
99. Di-Poi, N., N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne. 2002. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell. 10: 721-733.
100. Bhagavathula, N., K. C. Nerusu, A. Lal, C. N. Ellis, A. Chittiboyina, M. A. Avery, C. I. Ho, S. C. Benson, H. A. Pershadsingh, T. W. Kurtz, et al. 2004. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J. Invest. Dermatol. 122: 130-139.
101. He, G., P. Thuillier, and S. M. Fischer. 2004. Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. J. Invest. Dermatol. 123: 1110-1119.
102. Demerjian, M., M. Q. Man, E. H. Choi, B. E. Brown, D. Crumrine, S. Chang, T. Mauro, P. M. Elias, and K. R. Feingold. 2006. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp. Dermatol. 15: 154-160.
103. Thuillier, P., G. J. Anchiraico, K. P. Nickel, R. E. Maldve, I. Gimenez-Conti, S. J. Muga, K. L. Liu, S. M. Fischer, and M. A. Belury. 2000. Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol. Carcinog. 29: 134-142.
104. Chen, D., and K. Auborn. 1999. Fish oil constituent docosahexaenoic acid selectively inhibits growth of human papillomavirus immortalized keratinocytes. Carcinogenesis. 20: 249-254.
105. He, G., S. Muga, P. Thuillier, R. A. Lubet, and S. M. Fischer. 2005. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin. Mol. Carcinog. 43: 198-206.
106. Nicol, C. J., M. Yoon, J. M. Ward, M. Yamashita, K. Fukamachi, J. M. Peters, and F. J. Gonzalez. 2004. PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis. 25: 1747-1755.
107. Jaeckel, E. C., S. Raja, J. Tan, S. K. Das, S. K. Dey, D. A. Girod, T. T. Tsue, and T. R. Sanford. 2001. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127: 1253-1259.
108. Nijsten, T., E. Geluyckens, C. Colpaert, and J. Lambert. 2005. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J. Cutan. Pathol. 32: 340-347.
109. Mossner, R., U. Schulz, U. Kruger, P. Middel, S. Schinner, L. Fuzesi, C. Neumann, and K. Reich. 2002. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J. Invest. Dermatol. 119: 576-582.
110. Mossner, R., P. Meyer, F. Jankowski, I. R. Konig, U. Kruger, S. Kammerer, G. Westphal, M. B. Boettger, C. Berking, C. Schmitt, et al. 2007. Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. Cancer Lett. 246: 218-223.
111. Muller-Brusselbach, S., M. Komhoff, M. Rieck, W. Meissner, K. Kaddatz, J. Adamkiewicz, B. Keil, K. J. Klose, R. Moll, A. D. Burdick, et al. 2007. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J. 26: 3686-3698.
112. Zhang, C., X. Ni, M. Konopleva, M. Andreeff, and M. Duvic. 2004. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3,12-dioxoolean-1,9-dien-28- oic acid) induces apoptosis in mycosis fungoides/Sezary syndrome cells. J. Invest. Dermatol. 123: 380-387.
113. Pershadsingh, H. A., S. C. Benson, and C. N. Ellis. 2005. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 4: 386-390.
114. Ellis, C. N., J. N. Barker, A. E. Haig, C. A. Parker, S. Daly, and D. A. Jayawardene. 2007. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am. J. Clin. Dermatol. 8: 93-102.
115. Shafiq, N., S. Malhotra, P. Pandhi, M. Gupta, B. Kumar, and K. Sandhu. 2005. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int. J. Dermatol. 44: 328-333.
116. Kuenzli, S., and J. H. Saurat. 2003. Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology. 206: 252-256.
117. Kuenzli, S., and J. H. Saurat. 2003. Peroxisome proliferator-activated receptors in cutaneous biology. Br. J. Dermatol. 149: 229-236.
118. Kuenzli, S., and J. H. Saurat. 2004. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr. Drug Targets. 3: 205-211.
119. Msika, P., C. De Belilovsky, B. Chadoutaud, and J. F. Nicolas. 2007. New natural PPAR-alpha agonist for childhood atopic dermatitis: dermocorticoid- sparing and quality of life improvement (Abstract). J. Am. Acad. Dermatol. 56: AB67.